{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:05:53Z","timestamp":1794373553280,"version":"4.9.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The chimeric monoclonal antibody cAC10, directed against CD30, induces growth arrest of CD30+ cell lines in vitro and has pronounced antitumor activity in severe combined immunodeficiency (SCID) mouse xenograft models of Hodgkin disease. We have significantly enhanced these activities by conjugating to cAC10 the cytotoxic agent monomethyl auristatin E (MMAE) to create the antibody-drug conjugate cAC10-vcMMAE. MMAE, a derivative of the cytotoxic tubulin modifier auristatin E, was covalently coupled to cAC10 through a valine-citrulline peptide linker. The drug was stably attached to the antibody, showing only a 2% release of MMAE following 10-day incubation in human plasma, but it was readily cleaved by lysosomal proteases after receptor-mediated internalization. Release of MMAE into the cytosol induced G2\/M-phase growth arrest and cell death through the induction of apoptosis. In vitro, cAC10-vcMMAE was highly potent and selective against CD30+ tumor lines (IC50 less than 10 ng\/mL) but was more than 300-fold less active on antigen-negative cells. In SCID mouse xenograft models of anaplastic large cell lymphoma or Hodgkin disease, cAC10-vcMMAE was efficacious at doses as low as 1 mg\/kg. Mice treated at 30 mg\/kg cAC10-vcMMAE showed no signs of toxicity. These data indicate that cAC10-vcMMAE may be a highly effective and selective therapy for the treatment of CD30+ neoplasias.<\/jats:p>","DOI":"10.1182\/blood-2003-01-0039","type":"journal-article","created":{"date-parts":[[2003,5,13]],"date-time":"2003-05-13T05:36:03Z","timestamp":1052804163000},"page":"1458-1465","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":840,"title":["cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity"],"prefix":"10.1182","volume":"102","author":[{"given":"Joseph A.","family":"Francisco","sequence":"first","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Cerveny","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon L.","family":"Meyer","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Mixan","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Klussman","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana F.","family":"Chace","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starr X.","family":"Rejniak","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine A.","family":"Gordon","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"DeBlanc","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Toki","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Leung","family":"Law","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana O.","family":"Doronina","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay B.","family":"Siegall","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Senter","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"Wahl","sequence":"additional","affiliation":[{"name":"From Seattle Genetics, Bothell, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218145369500_REF1","doi-asserted-by":"crossref","unstructured":"Kaudewitz P, Stein H, Burg G, Mason DY, Braun-Falco O. Atypical cells in lymphomatoid papulosis express the Hodgkin cell-associated antigen Ki-1. J Invest Dermatol.1986;86: 350-354.","DOI":"10.1111\/1523-1747.ep12285562"},{"key":"2020021218145369500_REF2","doi-asserted-by":"crossref","unstructured":"Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol.1999;90: 157-164.","DOI":"10.1006\/clim.1998.4636"},{"key":"2020021218145369500_REF3","doi-asserted-by":"crossref","unstructured":"Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol.2000;190: 613-618.","DOI":"10.1002\/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-0"},{"key":"2020021218145369500_REF4","doi-asserted-by":"crossref","unstructured":"Gerli R, Pitzalis C, Bistoni O, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol.2000;164: 4399-4407.","DOI":"10.4049\/jimmunol.164.8.4399"},{"key":"2020021218145369500_REF5","unstructured":"Ihn H, Yazawa N, Kubo M, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol.2000;27: 698-702."},{"key":"2020021218145369500_REF6","doi-asserted-by":"crossref","unstructured":"McMillan SA, McDonnell GV, Douglas JP, Hawkins SA. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. Acta Neurol Scand.2000;101: 239-243.","DOI":"10.1034\/j.1600-0404.2000.101004239.x"},{"key":"2020021218145369500_REF7","doi-asserted-by":"crossref","unstructured":"Falini B, Flenghi L, Fedeli L, et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol.1992;82: 38-45.","DOI":"10.1111\/j.1365-2141.1992.tb04591.x"},{"key":"2020021218145369500_REF8","doi-asserted-by":"crossref","unstructured":"Tazzari PL, Bolognesi A, de Totero D, et al. Ber-H2 (anti-CD30)\u2013saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. Br J Haematol.1992;81: 203-211.","DOI":"10.1111\/j.1365-2141.1992.tb08208.x"},{"key":"2020021218145369500_REF9","doi-asserted-by":"crossref","unstructured":"Matthey B, Engert A, Barth S. Recombinant immunotoxins for the treatment of Hodgkin's disease [review]. Int J Mol Med.2000;6: 509-514.","DOI":"10.3892\/ijmm.6.5.509"},{"key":"2020021218145369500_REF10","unstructured":"Schnell R, Staak O, Borchmann P, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res.2002;8: 1779-1786."},{"key":"2020021218145369500_REF11","doi-asserted-by":"crossref","unstructured":"Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol.2001;2: 313-325.","DOI":"10.2174\/1389201013378635"},{"key":"2020021218145369500_REF12","unstructured":"Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 mAb SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res.2002;62: 3736-3742."},{"key":"2020021218145369500_REF13","unstructured":"Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res.1995;55: 5335-5341."},{"key":"2020021218145369500_REF14","doi-asserted-by":"crossref","unstructured":"King KM, Younes A. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev Anticancer Ther.2001;1: 177-186.","DOI":"10.1586\/14737140.1.2.177"},{"key":"2020021218145369500_REF15","doi-asserted-by":"crossref","unstructured":"Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol.2002;20: 3262-3269.","DOI":"10.1200\/JCO.2002.11.017"},{"key":"2020021218145369500_REF16","doi-asserted-by":"crossref","unstructured":"Pettit GR. The dolastatins. Fortschr Chem Org Naturst.1997;70: 1-79.","DOI":"10.1007\/978-3-7091-6551-5_1"},{"key":"2020021218145369500_REF17","doi-asserted-by":"crossref","unstructured":"King HD, Dubowchik GM, Mastalerz H, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxy triethylene glycol chains. J Med Chem.2002;45: 4336-4343.","DOI":"10.1021\/jm020149g"},{"key":"2020021218145369500_REF18","doi-asserted-by":"crossref","unstructured":"Degnim AC, Morrow SE, Ku J, Zar HA, Nakayama DK. Nitric oxide inhibits peroxide-mediated endothelial toxicity. J Surg Res.1998; 75: 127-134.","DOI":"10.1006\/jsre.1998.5270"},{"key":"2020021218145369500_REF19","doi-asserted-by":"crossref","unstructured":"Dubowchik GM, Mosure K, Knipe JO, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs, 2: models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett.1998;8: 3347-3352.","DOI":"10.1016\/S0960-894X(98)00610-6"},{"key":"2020021218145369500_REF20","doi-asserted-by":"crossref","unstructured":"Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol.2003;21: 778-784.","DOI":"10.1038\/nbt832"},{"key":"2020021218145369500_REF21","doi-asserted-by":"crossref","unstructured":"Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER. Functional effects of CD30 on a large granular lymphoma cell line, YT: inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J Immunol.1993;151: 5896-5906.","DOI":"10.4049\/jimmunol.151.11.5896"},{"key":"2020021218145369500_REF22","doi-asserted-by":"crossref","unstructured":"Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83: 2045-2056.","DOI":"10.1182\/blood.V83.8.2045.2045"},{"key":"2020021218145369500_REF23","doi-asserted-by":"crossref","unstructured":"Hubinger G, Muller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1\/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene.2001;20: 590-598.","DOI":"10.1038\/sj.onc.1204128"},{"key":"2020021218145369500_REF24","doi-asserted-by":"crossref","unstructured":"Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol.1999;44: 395-402.","DOI":"10.1007\/s002800050995"},{"key":"2020021218145369500_REF25","doi-asserted-by":"crossref","unstructured":"Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene.2000;19: 6144-6151.","DOI":"10.1038\/sj.onc.1204000"},{"key":"2020021218145369500_REF26","doi-asserted-by":"crossref","unstructured":"Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia.2002;16: 1627-1636.","DOI":"10.1038\/sj.leu.2402677"},{"key":"2020021218145369500_REF27","doi-asserted-by":"crossref","unstructured":"Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol.2000; 18: 2282-2292.","DOI":"10.1200\/JCO.2000.18.11.2282"},{"key":"2020021218145369500_REF28","doi-asserted-by":"crossref","unstructured":"Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A. 1996;93: 8618-8623.","DOI":"10.1073\/pnas.93.16.8618"},{"key":"2020021218145369500_REF29","unstructured":"Braslawsky GR, Edson MA, Pearce W, Kaneko T, Greenfield RS. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. Cancer Res.1990;50: 6608-6614."},{"key":"2020021218145369500_REF30","doi-asserted-by":"crossref","unstructured":"Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia: choice of linker. Bioconjug Chem.2002;13: 40-46.","DOI":"10.1021\/bc0100206"},{"key":"2020021218145369500_REF31","doi-asserted-by":"crossref","unstructured":"Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem.2002;13: 47-58.","DOI":"10.1021\/bc010021y"},{"key":"2020021218145369500_REF32","doi-asserted-by":"crossref","unstructured":"Dubowchik GM, Firestone RA, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem.2002;13: 855-869.","DOI":"10.1021\/bc025536j"},{"key":"2020021218145369500_REF33","doi-asserted-by":"crossref","unstructured":"Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis. Nat Med.1996;2: 72-79.","DOI":"10.1038\/nm0196-72"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/4\/1458\/1689263\/h81603001458.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/4\/1458\/1689263\/h81603001458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T07:02:45Z","timestamp":1682492565000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/4\/1458\/17083\/cAC10vcMMAE-an-antiCD30monomethyl-auristatin-E"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,15]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-01-0039","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,15]]}}}